Log in
Providing a VOICE for Wisconsin's MULTIDISCIPLINARY CANCER CARE TEAMs and the PATIENTS THEY SERVE since 1991
Join/Renew
About
About Us
Executive Office
Leadership
Community (Members Only)
Meetings & Education
Upcoming Events
Poster Presentations
Articles and Podcasts
Allied Health Professionals Award
WAHO 2025 Fellows Program
Advocacy
Advocacy Support
Patient Advocacy Organizations
White Bagging
Advocacy Resources
Resources
State & Federal Resources
Financial Advocacy & Patient Assistance
Find A Clinical Trial
Off-Label Use Literature
Jobs
Latest News
Educational Resources
Adolescent and Young Adult Cancer Resources
Industry
Corporate Members
Exhibitor Information
Industry News
Industry News
FDA Approves Pembrolizumab + Axitinib for Advanced Renal Cell Carcinoma
On April 19, the FDA approved pembrolizumab (Keytruda, Merck & Co. Inc.) plus axitinib (Inlyta, Pfizer Inc.) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Read the full FDA press release here
.
Posted 4/22/2019